4-(3-imidazol-1-yl-phenyl)-7-isobutylamino-8-trifluoromethyl-1,3-dihydro-benzo[b][1,4]diazepin-2-one | 473551-76-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-(3-imidazol-1-yl-phenyl)-7-isobutylamino-8-trifluoromethyl-1,3-dihydro-benzo[b][1,4]diazepin-2-one
• 英文别名: 4-(3-imidazol-1-ylphenyl)-7-(2-methylpropylamino)-8-(trifluoromethyl)-1,3-dihydro-1,5-benzodiazepin-2-one
• CAS: 473551-76-7
• 化学式: C₂₃H₂₂F₃N₅O
• 分子量: 441.456
• InChiKey: SLZWQLBLGIMSRX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  32
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  71.3
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  {2-[3-(3-imidazol-1-yl-phenyl)-3-oxo-propionylamino]-5-isobutylamino-4-trifluoromethyl-phenyl}-carbamic acid tert-butyl ester 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 生成 4-(3-imidazol-1-yl-phenyl)-7-isobutylamino-8-trifluoromethyl-1,3-dihydro-benzo[b][1,4]diazepin-2-one
  参考文献：
  名称：

  Synthesis and characterization of 1,3-dihydro-benzo[b][1,4]diazepin-2-one derivatives: Part 3. New potent non-competitive metabotropic glutamate receptor 2/3 antagonists

  摘要：

  A series of 1,3-dihydro-benzo[b][1,4]diazepin-2-one derivatives was evaluated as non-competitive mGluR2/3 antagonists. Replacement of the (2-aryl)-ethynyl-moiety in 8-position with smaller less lipophilic substituents produced compounds inhibiting the binding of [3H]-LY354740 to rat mGluR2 with low nanomolar affinity and consistent functional effect at both mGluR2 and mGluR3. These compounds were able to reverse LY354740-mediated inhibition of field excitatory postsynaptic potentials in the rat dentate gyrus and in vivo activity could be demonstrated by reversal of the LY354740-induced hypoactivity in mice after oral administration. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.02.076

文献信息

• Dihydro-benzo [b] [1,4] diazepin-2-one derivatives
  申请人：——

  公开号：US20020193367A1

  公开（公告）日：2002-12-19

  This invention is a dihydro-benzo[b][1,4]diazepin-2-one derivative of the formula 1 wherein R 1 , R 2 , R 3 , X and Y are as defined in the specification. The invention includes pharmaceutical compositions containing these compounds, a process for their preparation, their use in preparation of pharmaceutical compositions and administration of an effective amount of the compounds for the treatment or prevention of acute and/or chronic neurological disorders to a patient in need of such treatment.

  这项发明涉及一种公式1中R1、R2、R3、X和Y如规范中所定义的二氢苯并[b][1,4]二氮杂环-2-酮衍生物。该发明包括含有这些化合物的药物组合物、制备它们的方法、它们在制备药物组合物时的使用以及给需要这种治疗的患者施用足够剂量的这些化合物以治疗或预防急性和/或慢性神经系统疾病。
• Dihydro-benzo [b][1,4]diazepin-2-one derivatives
  申请人：Hoffman-La Roche Inc.

  公开号：US06544985B2

  公开（公告）日：2003-04-08

  This invention is a dihydro-benzo[b][1,4]diazepin-2-one derivative of the formula wherein R1, R2, R3, X and Y are as defined in the specification. The invention includes pharmaceutical compositions containing these compounds, a process for their preparation, their use in preparation of pharmaceutical compositions and administration of an effective amount of the compounds for the treatment or prevention of acute and/or chronic neurological disorders to a patient in need of such treatment.

  这项发明涉及一种二氢苯并[b][1,4]二氮杂环-2-酮衍生物，其化学式中R1、R2、R3、X和Y如规范中所定义。该发明包括含有这些化合物的制药组合物，制备这些化合物的方法，以及向需要治疗急性和/或慢性神经系统疾病的患者施用有效量的这些化合物用于制备制药组合物及治疗或预防这些疾病的方法。
• DIHYDRO-BENZO (b) (1, 4) DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II
  申请人：F. Hoffmann-La Roche AG

  公开号：EP1379511B1

  公开（公告）日：2005-07-20
• US6544985B2
  申请人：——

  公开号：US6544985B2

  公开（公告）日：2003-04-08
• Synthesis and characterization of 1,3-dihydro-benzo[b][1,4]diazepin-2-one derivatives: Part 3. New potent non-competitive metabotropic glutamate receptor 2/3 antagonists
  作者：Thomas J. Woltering、Jürgen Wichmann、Erwin Goetschi、Geo Adam、James N.C. Kew、Frédéric Knoflach、Theresa M. Ballard、Jörg Huwyler、Vincent Mutel、Silvia Gatti

  DOI：10.1016/j.bmcl.2008.02.076

  日期：2008.4

  A series of 1,3-dihydro-benzo[b][1,4]diazepin-2-one derivatives was evaluated as non-competitive mGluR2/3 antagonists. Replacement of the (2-aryl)-ethynyl-moiety in 8-position with smaller less lipophilic substituents produced compounds inhibiting the binding of [3H]-LY354740 to rat mGluR2 with low nanomolar affinity and consistent functional effect at both mGluR2 and mGluR3. These compounds were able to reverse LY354740-mediated inhibition of field excitatory postsynaptic potentials in the rat dentate gyrus and in vivo activity could be demonstrated by reversal of the LY354740-induced hypoactivity in mice after oral administration. (C) 2008 Elsevier Ltd. All rights reserved.